Cancer KOL Commentaries - Cancer KOL Commentary Primary and novel androgen deprivation therapy for prostate cancer: balancing efficacy and potential toxicitiesMary-Ellen Taplin VIEW MORE Case study Case Study (2019-2023): Changing treatmentsMary-Ellen Taplin VIEW MORE Case study mHSPC: A Clinical Case StudyJordan Ciuro & Atish Choudhury VIEW MORE KOL Commentary Updates in mHSPC ASCO Genitourinary Symposium 2023Atish Choudhury & Jordan Ciuro VIEW MORE Infographics- Cancer Biomarkers for the Prediction of Disease Progression, Prognosis, and Treatment Response of Metastatic Prostate Cancer VIEW INFOGRAPHIC Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer VIEW INFOGRAPHIC Articles - Cancer Cancer treatment and survivorship statistics, 2022 READ MORE Prostate-specific antigen levels of ≤4 and >4 ng/mL and risk of prostate cancer-specific mortality in men with biopsy Gleason score 9 to 10 prostate cancer READ MORE Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer–specific mortality READ MORE Facebook Twitter Linkedin
